Literature DB >> 7632359

p53 immunoreactivity in astrocytomas and its relationship to survival.

S al-Sarraj1, L R Bridges.   

Abstract

p53 is a putative tumour suppressor gene implicated in a wide range of human malignancies. Mutation of p53 gene results in a more stable product and increased quantities of p53 protein in the cell. Thus, unlike the normal situation, mutated p53 is detectable by immunohistochemistry. We stained frozen sections of 74 astrocytomas with two antibodies to p53, PAb 1801 and PAb 421. Overall 18/74 (24%) of astrocytomas showed p53 immunoreactivity. Fifteen of 47 (32%) grade IV were p53 immunopositive, as were 3/16 (19%) grade III, 0/7 (0%) grade II and 0/4 (0%) grade I astrocytomas. These findings are in agreement with previous studies in showing relatively greater numbers of high grade than low grade p53 immunopositive tumours. Although we found an expected difference in survival according to grade, there was no significant difference in survival (p > 0.1) between p53 immunopositive and immunonegative tumours. We conclude that, whilst p53 undoubtedly plays an important role in the molecular 'chain' leading to malignancy in some astrocytomas, within tumours of comparable grade it does not appear to influence survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632359     DOI: 10.1080/02688699550041476

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  7 in total

1.  Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.

Authors:  Kaisorn L Chaichana; Aditya N Halthore; Scott L Parker; Alessandro Olivi; Jon D Weingart; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  J Neurosurg       Date:  2010-06-04       Impact factor: 5.115

Review 2.  P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.

Authors:  Georgia Levidou; Elias El-Habr; Angelica A Saetta; Christine Bamias; Klea Katsouyanni; Klea Katsougiannis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  J Neurooncol       Date:  2010-05-12       Impact factor: 4.130

3.  Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.

Authors:  Mart A A M Heesters; Jan Koudstaal; K Gwan Go; Willemina M Molenaar
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

4.  Immunohistochemical markers for prognosis of anaplastic astrocytomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

5.  Immunohistochemical markers for prognosis of cerebral glioblastomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

6.  Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.

Authors:  Stella M Ranuncolo; Mirta Varela; Ana Morandi; José Lastiri; Silvia Christiansen; Elisa Bal de Kier Joffé; María G Pallotta; Lydia Puricelli
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

7.  Proliferation and aneusomy predict survival of young patients with astrocytoma grade II.

Authors:  P H Wessels; A H N Hopman; B Kubat; A G H Kessels; E W Hoving; M I J Ummelen; F C S Ramaekers; A Twijnstra
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.